Gene therapy has finally made it over the hump.
After decades of research and some devastating setbacks, major technical hurdles have been overcome, opening up the long-anticipated promise of this field. A new approval has buoyed interest, pipelines are bubbling with new candidates and big investments are being made.
Two gene therapies have hit the European market and the first is expected to hit the U.S. market as early as next year. Beyond that, there is a growing pipeline rapidly coming forward.
All this is fueling high hopes of actual cures for previously incurable diseases and big profits. So whats the rub?
The first ever approved gene therapy was Shenzhen SiBiono GenTechs Gendicine, a recombinant Ad-p53 gene therapy for head and neck cancer, which launched in China in 2004. But it was Glybera's (alipogene tiparvovec) approval in fall 2012 that sparked investor interest in gene therapy. For a while that drug reigned as the most expensive treatment in history, costing more than $1 million per patient.
Glybera turned out to be a disappointment due to the high price tag. The drug restores lipoprotein lipase enzyme activity in patients with LPL deficiency (an ultra rare disease), but the drug comes with the severe side effect of pancreatitis. After use by only one patient and five years on the European market, maker uniQure chose not to seek renewal of its European approval this fall and is not pursuing U.S. approval.
Despite the failure of Glybera, GlaxoSmithKlines Strimvelis has further fueled investor interest with its approval in Europe in May 2016.
Strimvelis treats severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency. It is estimated that about a couple dozen children per year are diagnosed with ADA-SCID in the U.S. and Europe combined. One year on the market, the British pharma has confirmed that one patient has been treated with the drug. "A patient has been treated with Strimvelis and others have been referred and are currently being assessed for eligibility to receive the drug," GSK spokesperson Anna Padula told BioPharma Dive.
After the Glybera debacle, GSKs experience with Strimvelis will be telling, but there are also some up-and-coming gene therapies that may teach us more.
Gene therapy was originally regarded as one of those "no-brainer"approaches to curing genetically caused diseases. After all, if the DNA is broken, why not just fix it? Unfortunately, it turned out to be much more complicated.
Many of the challenges are around how new DNA is incorporated. One choice is to inject a viral vector attached to a payload that naturally integrates its genetic material into that of the patients. The other choice is to remove the patients cells, modify them, and return them, a process known as ex vivo therapy.
One of the early fears was that DNA would incorporate in the wrong place thereby not fixing the error, as well as creating a new one. That turned out to be a real worry with some of the first vectors, reinforced by early gene therapy treatments for SCIDS that led to T-cell leukemia in some treated boys. At least one of those boys died from the cancer they developed.
Further, there was the tragedy of Jesse Gelsingers death at the University of Pennsylvanias Institute of Human Gene Therapy in 1999. Eighteen-year-old Gelsinger was taking part in a trial aimed at treating ornithine transcarbamylase deficiency, but just days after receiving the therapy he died of massive organ failure, likely sparked by an immune reaction to the adeno-viral vector used.
Then there were treatments that just didnt work. Avigens gene therapy worked well in animals, producing adequate Factor IX levels for several years in models of hemophilia. But in clinical trials, only one patient responded, and that response lasted only four weeks. The patient, as one observer noted, had "touched the rainbow" only to watch it fade from view.
Beyond efficacy, manufacturing is still a challenge. "But we are getting better at that and in the selection of indications," said Scott Burger, principal at Advanced Cell and Gene Therapy. Because gene therapy is such a young field, Burger noted that "long-term monitoring of patients will be key." The boys who developed leukemia in the early SCID trial were all diagnosed a couple of years after treatment.
Every field has its ups and downs, but these tragic events left gene therapy with tremendous baggage. Still, some dogged proponents have soldiered on, and the news now more than a decade later seems to be getting a lot better.
"A new generation of vectors have dramatically improved the prospects for this field," said Geoff MacKay, President and CEO of AvroBio. "There are now hundreds of gene therapies that are in trials and many of them are a one time cure."
News about promising gene therapies in the clinic is sprouting up all the time.
BioMarin has a gene therapy for hemophilia A in Phase 2b. "We are far ahead in the development process and could potentially market the first gene therapy for this condition," said company spokesperson Debra Charlesworth. "The physician and patient community will be looking for strong clinical data," she added. "In addition we have commissioned a gene therapy manufacturing facility that will come online in the middle of this year."
GSK has a license to develop multiple new gene therapies with Fondazione Telethon and Ospedale San Raffaele, the same groups that helped produce Strimvelis. The agreement covers six additional treatments, including one for metachromatic leukodystrophy and one for Wiskott-Aldrich Syndrome. Padula reports that both of these are in clinical trials.
The next wave of gene therapies will focus on rare diseases like hemophilia and even inherited forms of blindness.Spark Therapeutics, for example,recently submitted a Biologics License Application (BLA) with the FDA for voretigene neparvovec, a gene therapy for the treatment of vision loss due to biallelic RPE65 mutation-associated retinal disease.
And Pfizer has inked deals with both Spark and Sangamo for gene therapies to treat different forms of hemophilia. Meanwhile, Biogen spin-off Bioverativhas picked up two gene therapies from Sangamo.
Scientific challenges remain considerable, though, and pricing will clearly be one of the biggest hurdles for gene therapies going forward. "Todays challenges are all around building a viable business model," said MacKay. That has not dampened enthusiasm for the blossoming field that has been rising and falling out of favor for at least two decades.
See original here:
A new wave of gene therapies ready to hit US shores - BioPharma Dive
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]